AeonClad Coatings has launched of a new subsidiary that will focus on biomedical applications. AeonClad Biomedical LLC is expected to utilize the company’s AeonCoat dry coating technology that would be used to coat and encapsulate drugs or active pharmaceutical ingredients. The product is designed to enable custom-made coatings for improved dissolution of poorly water soluble drugs, as well as modified or sustained release, according to the company. Coatings can also display functional groups used for secondary covalent coupling of biological materials or for targeted drug delivery. Medical device coatings is the most rapidly expanding sector of the $213 billion medical device market, the company said.